Mitch Machtay.

.. Mitch Machtay, the Seidman Cancer Center Research Manager at University Hospitals Case Medical Center and the principle of the study, presented the key data today by 2 clock at the annual meeting of the American Society for Radiation Oncology in Miami Beach, Fla. The National Cancer Institute funded study the the American College of Radiology Imaging Network in collaboration with Radiation Therapy Oncology Group , 251 patients wrote at 60 cancer centers across the country. Is the number one is the number one cancer killer in the United States remains These results have the potential to cancer doctors a new tool to more effectively customized treatments for patients with locally advanced lung cancer says Dr.

In this study had stage III lung cancer patients before and after PET scans a combined treatment with chemotherapy and radiotherapy. They measured how quickly tumors a radioactive sugar molecule to absorb . Since most cancer cells absorb sugar at a higher rate than normal cells, lung cancer.e tumor usually shines brightly on PET scans.

The results also showed that there is a strong correlation between the dose of radiation intensity, and local control of the cancer, which suggests that further research must be carried out in radiation technology for lung cancer.Candidate for president Sen. Hillary Rodham Clinton on their healthcare suggestion on campaign rally in Des Moines, plans Reuters / Washington Post report Reuters Reuters / Washington Post, Clinton details of the proposal details of the proposal are available.

Those proof-of concept study is to safety and tolerability of safety and tolerability after three months of metering of CS-917, and its impact on the blood levels the molecule A1C, an important means to the blood sugar control in subjects with type 2 diabetes.

A included 392 patient at over 100 sites in the this randomized, double – blind, placebo – controlled study of. Patients uniformly spread in four groups consists two active dose group out of CS-917, an active comparator and placebo. If successful, the study could supports choice of dose for a Phase 3 study. Are urgently needed successfully completing two Phase 2a clinical trials for patients have type 2 diabetic, CS-917 been well tolerated significantly reduction the elevated blood glucose levels the disease is the disease.